Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

VBH

- PMLiVE

Novartis negotiates ex-US rights to Spark gene therapy

Strikes $170m deal for Luxturna

Novartis day

Novartis doubles down on biosimilars with Biocon alliance

The companies will develop multiple immunology and oncology biosimilars

- PMLiVE

Novartis gets speedy reviews for new Kymriah filings

US and EU regulatory agencies will review the drug for DLBCL patients

2018 by Darwin

Our industry’s evolution can’t be predicted, but it can be foreseen

- PMLiVE

Novartis joins biosimilar Humira push in US

Pharma giant hopes its candidate will follow in the footsteps of Amgen’s Amjevita and BI’s Cyltezo

Through the Looking Glass

Non-traditional innovation

- PMLiVE

Pfizer’s Elizabeth Barrett joins Novartis as its oncology head

She succeeds Bruno Strigini who retires

Transforming access in rare diseases

A quiet revolution is underway that could transform access to medicines in rare diseases, according to Duchenne UK, the charity at the heart of a new project to streamline evidence-gathering...

- PMLiVE

Novartis’ Cosentyx takes on Humira and biosimilar in phase III showdown

The head-to-head trials will evaluate findings in patients with PsA and AS

- PMLiVE

Novartis’ Promacta receives US breakthrough therapy designation

Regulatory filings of the rare blood disorder treatment are expected this year

- PMLiVE

Novartis bags new breakthrough status for Kisqali in breast cancer

The Swiss pharma group’s treatment will rival Lilly’s Verzenio and Pfizer’s Ibrance if approved

- PMLiVE

Delivering real patient value

Three practical steps to achieving a patient-focused comms plan

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links